On 5 September 2024, Novo Nordisk filed separate lawsuits in the US District Court for the District of Delaware against each of Sun Pharmaceutical and Mylan asserting infringement of US patent number 12,029,779 (granted 9 July 2024), which claims a method of reducing body weight by administering semaglutide. The litigation reportedly follows the filing by Sun Pharmaceutical and Mylan of abbreviated new drug applications (ANDA) with the FDA for approval of generic versions of Novo Nordisk’s Wegovy® (semaglutide).
Novo Nordisk has previously taken legal action to prevent counterfeit versions of Ozempic® (semaglutide) and Wegovy® (semaglutide) from being sold in the US. Litigation against two clinics settled in February 2024, with the companies involved being permanently banned from claiming their products are approved by the FDA and from using any Novo Nordisk logos or trade marks. Additional US litigation regarding sale of compounded “semaglutide” was commenced by Novo Nordisk in May 2024.